Nuvation Bio Inc. (NUVB)
NYSE: NUVB · Real-Time Price · USD
4.920
+0.160 (3.36%)
At close: Jun 12, 2026, 4:00 PM EDT
4.967
+0.047 (0.96%)
Pre-market: Jun 15, 2026, 8:11 AM EDT
Nuvation Bio Employees
Nuvation Bio had 307 employees as of March 31, 2026. The number of employees increased by 34 or 12.45% compared to the same quarter last year.
Employees
307
Change
34
Growth
12.45%
Revenue / Employee
$465,948
Profits / Employee
-$475,550
Market Cap
1.71B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 307 | 34 | 12.45% |
| Dec 31, 2025 | 298 | 78 | 35.45% |
| Sep 30, 2025 | 291 | 88 | 43.35% |
| Jun 30, 2025 | 278 | 111 | 66.47% |
| Mar 31, 2025 | 273 | 114 | 71.70% |
| Dec 31, 2024 | 220 | 169 | 331.37% |
| Sep 30, 2024 | 203 | 150 | 283.02% |
| Jun 30, 2024 | 167 | 113 | 209.26% |
| Mar 31, 2024 | 159 | 106 | 200.00% |
| Dec 31, 2023 | 51 | -2 | -3.77% |
| Sep 30, 2023 | 53 | -1 | -1.85% |
| Jun 30, 2023 | 54 | -31 | -36.47% |
| Mar 31, 2023 | 53 | -15 | -22.06% |
| Dec 31, 2022 | 53 | -11 | -17.19% |
| Sep 30, 2022 | 54 | -4 | -6.90% |
| Jun 30, 2022 | 85 | 34 | 66.67% |
| Mar 31, 2022 | 68 | 30 | 78.95% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Recursion Pharmaceuticals | 600 |
| Agios Pharmaceuticals | 540 |
| Intellia Therapeutics | 377 |
| Nurix Therapeutics | 317 |
| Biohaven | 274 |
| Zymeworks | 243 |
| uniQure | 221 |
| Innoviva | 159 |
NUVB News
- 11 days ago - Nuvation Bio Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 18 days ago - Nuvation Bio to Present at the Jefferies Global Healthcare Conference - PRNewsWire
- 18 days ago - Nuvation Bio’s Ibtrozi shows improved quality of life in NSCLC trial - TheFly
- 19 days ago - Nuvation Bio to Present New Quality-of-Life Data for IBTROZI® (Taletrectinib) in Patients with ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2026 Annual Meeting - PRNewsWire
- 19 days ago - Nuvation Bio Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA - Transcripts
- 24 days ago - Nuvation Bio Transcript: AGM 2026 - Transcripts
- 25 days ago - Nuvation Bio Transcript: RBC Capital Markets Global Healthcare Conference 2026 - Transcripts
- 26 days ago - Nuvation Bio Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference - Transcripts